Navigation Links
Multiple Sclerosis (MS) Industry Trends and 2018 Market Opportunities Analyzed in New Research Report at MarketReportsOnline.com
Date:11/30/2013

Dallas, Texas (PRWEB) November 30, 2013

The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated with the global multiple sclerosis market. The report analyzes the various causes and symptoms related to the prevalence of MS in patients. Further, the report analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Also, the domestic market of United States which is the largest contributor to the global multiple sclerosis market has been assessed. The report concludes with a brief discussion of major factors driving the global multiple sclerosis market and profiles major players like Teva, Biogen Idec, Merck KGaA, Bayer and Novartis. Complete report available at http://www.marketreportsonline.com/295943.html.

Geographical Coverage: Global and United States

Company Coverage: Teva, Biogen Idec, Merck KGaA, Bayer and Novartis
The global Multiple Sclerosis market is undergoing drastic change since the last few years. The rising diagnosis and treatment rate coupled with growing investment in research and development has played a key role in the determining the growth dynamics of the global Multiple Sclerosis (MS) market.

Currently, MS is known to affect an estimated 2.5 million people around the world with around 5000 new cases emerging each year. Since there is no particular cure or treatment for multiple sclerosis, the market is currently dominated by few drugs and medication like Copaxone, Avonex, Betaseron and Extavia which delay or reduce the progression of multiple sclerosis in individuals.

Purchase a copy of this report at http://www.marketreportsonline.com/contacts/purchase.php?name=295943.

Until the last year, MS market was led by self injectables drugs such as Capaxone and Avonex that caused side effects like swelling, anxiety, redness and difficult breathing. To address these shortcomings and side effects, pharmaceutical companies developed oral drugs that are considered safe and effective. With the beginning of 2013, oral drugs such as Gilenya and Aubagio witnessed rapid demand due to their higher efficacy and better results. In addition, there are many drugs down the pipeline that would change the dynamics and growth of the multiple sclerosis market in future. For instance, Teva hopes its Copaxone successor, laquinimod, may help it preserve some market share when Copaxone loses patent protection.

Few Points from Table of Contents (http://www.marketreportsonline.com/295943-toc.html .) listed below:
1. Executive Summary
2. Global Multiple Sclerosis Market: An Overview
3. Global Multiple Sclerosis Market: An Analysis
4. Multiple Sclerosis Market: Country Analysis
5. Growth Drivers of Multiple Sclerosis Market
6. Company Profiles: Multiple Sclerosis Market

List of Figures
Figure 1: Multiple Sclerosis Diagrammatic Overview
Figure 2: Global Multiple Sclerosis Market Size, 2007-12 (US$ Million)
Figure 3: Global Multiple Sclerosis Market Size Forecast, 2013-18 (US$ Million)
Figure 4: Global Multiple Sclerosis Patients, 2007-12
Figure 5: Global Multiple Sclerosis Patients Forecast, 2013-18
Figure 6: Global Multiple Sclerosis Market, By Major Players, By Value (2012)
Figure 7: Global Multiple Sclerosis Market Share Analysis, By Geography, 2007-12
Figure 8: Global Multiple Sclerosis Competitor Share shift, 2013-16
Figure 9: Average Revenue per Patient, By Region, 2007-2012 (US$ Thousands)
Figure 10: United states Multiple Sclerosis Market, 2007-12 (US$ Million)
Figure 11: United states Multiple Sclerosis Market Forecast, 2013-18 (US$ Million)
Figure 12: United States Multiple Sclerosis Patients, 2007-12
Figure 13: United States Multiple Sclerosis Patients Forecast, 2013-18
Figure 14: Number of Multiple Sclerosis Patients Worldwide, 2010-2016E
Figure 15: Global Healthcare Expenditure, 2007-2012 (US$ Trillion)
Figure 16: Copaxone Sales, By Region, FY'2011-FY'13
Figure 17: Biogen Idec Global Sales, 2008-2012 (US$ Million)
Figure 18: Global Rebif Sales, 2008-2012 (US$ Million)
Figure 19: Merck Rebif Sales, By Region (2012)
Figure 20: Global Betaseron Sales, 2008-2012 (US$ Million)
Figure 21: Bayer's Pharmaceuticals Global Sales, By Region (2012)
Figure 22: Global Extavia Net Sales, 2008-2012 (US$ Million)
Table 1: Most Common Drugs used for Treating Multiple sclerosis
Table 2: Product Sales of Avonex & Tysabri, 2008-12 (US$ Million)

Explore more reports on Pharmaceuticals market @ http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:
MarketReportsOnline.com is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 supports to our customers through phone and email communication.

Read the full story at http://www.prweb.com/releases/global-multiple-sclerosis/market/prweb11380179.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Buyers and sellers ... users to dispensaries and head shops –can’t help but be heartened by the industry’s ... tell-tale cannabis odor aptly described as “skunk smell.” At last they can simply, ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... , ... As part of the nationwide Days of Remembrance effort led by ... and Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that ... to Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: